Sepracor named Adrian Adams CEO, replacing Timothy Barberich, who was elected executive chairman of the company’s board of directors. Adams appointment had been anticipated since his hiring as COO on March 1. Adams, who will retain title of president, was previously CEO at Kos Pharmaceuticals from 2002 until the acquisition of the company by Abbott Laboratories in December 2006 for $3.7 billion. Adams is a 30-year veteran of the pharmaceutical industry with experience in national and international product marketing, R&D, sales, business development and general management with companies including ICI, SmithKline Beecham and Novartis.
Gary Croft has joined Merz Pharmaceuticals US, a division of Germany-based Merz Pharmaceuticals, as VP of marketing. Prior to joining Merz, Croft was director of sales, Americas for the Colbar Aesthetics division of Johnson & Johnson and was previously responsible for the global commercialization strategy for J&J's aesthetics business. His experience also includes a variety of marketing and sales management positions at Medicis and GlaxoSmithKline. Croft will oversee all marketing activities for Merz Pharmaceuticals US and report to Terry Conrad, president of Merz Pharmaceuticals U.S. Croft spent his early years in the United Kingdom where he earned a bachelor’s in economics. He spent the majority of his working career in the US, including 14 years with GlaxoSmithKline.
Vox Medica has added Kelly Brightbill as an associate consultant in the strategic solutions group. Brightbill will assist the unit with consulting for both internal and external clients, developing strategies for client projects, and working with Vox Medica branding and marketing initiatives. Brightbill joins Vox Medica from Johnson & Johnson, where she served as a sales representative for Ortho-McNeil Neurologics. She managed a territory in the greater Philadelphia area serving more than 120 doctors specializing in primary care and neurology.